The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 57.00
Bid: 56.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.571%)
Open: 57.00
High: 57.00
Low: 57.00
Prev. Close: 57.00
MAV4 Live PriceLast checked at -
Maven Income and Growth VCT 4 is an Investment Trust

To achieve long term capital appreciation and generate income by investing the majority of its funds in a diversified portfolio of shares and securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re Offer for Subscription

16 Feb 2023 07:00

RNS Number : 0561Q
Maven Income & Growth VCT 4 PLC
16 February 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

 

Maven Income and Growth VCT 4 PLC (the Company)

 

Offer for Subscription

 

16 February 2023

 

On 7 October 2022, alongside the other Maven VCTs, the Company announced the publication of a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to an offer for subscription of new Ordinary Shares of 10p each (the "Offer").

 

The Board of the Company is pleased to advise that, with valid subscriptions received to date under the Offer now approaching its initial fundraising target of £5 million, and in view of continued interest from potential investors, the Directors have resolved to utilise the over-allotment facility, as provided for under the terms and conditions of the Offer to the extent required to meet further investor demand.

 

The deadline for receipt of applications for the Offer is 12.00 noon on 4 April 2023 in relation to the tax year 2022/23 and 12.00 noon on 26 May 2023 in relation to the tax year 2023/24. The Offer will close on 31 May 2023 unless it is fully subscribed by an earlier date or extended by the Board to no later than 6 October 2023.

 

Downloadable versions of the Prospectus documents are available at: mavencp.com/vctoffer.

 

Any enquiries in respect of the Offer, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com  

Maven Capital Partners UK LLPSecretary

The information contained within this announcement is deemed by the Companies to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

Notes

This announcement does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase, any investment in any jurisdiction, nor shall it (or the fact of its distribution) form the basis of, or be relied on in connection with, any contract therefor.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRGPUMCPUPWGAA
Date   Source Headline
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)
9th Nov 20233:49 pmRNSResult of General Meeting
13th Oct 20234:56 pmRNSPublication of a Prospectus
13th Oct 202310:17 amRNSDirector/PDMR Shareholding
13th Oct 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
6th Oct 20232:39 pmRNSStatement re Dividend Investment Scheme
8th Sep 20235:01 pmRNSTransaction in Own Shares-Corrective announcement
7th Sep 20233:35 pmRNSTransaction in Own Shares
30th Aug 20232:02 pmRNSHalf-year Report
17th Aug 20233:26 pmRNSStatement re NAV and Interim Dividend
12th Jul 20234:09 pmRNSHolding(s) in Company
10th Jul 20235:06 pmRNSHolding(s) in Company
2nd Jun 202310:05 amRNSDirector/PDMR Shareholding
2nd Jun 20239:43 amRNSIssue of Equity
24th May 20235:10 pmRNSTransaction in Own Shares
23rd May 202310:18 amRNSDirector/PDMR Shareholding
23rd May 202310:17 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20233:38 pmRNSNet Asset Value(s) - Dividend Investment Scheme
11th May 20233:01 pmRNSResult of AGM
11th May 20232:20 pmRNSNet Asset Value(s)
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
13th Apr 20237:00 amRNSAnnual Financial Report
5th Apr 202312:36 pmRNSDirector/PDMR Shareholding
5th Apr 202312:30 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
21st Mar 20234:08 pmRNSTransaction in Own Shares
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:11 pmRNSUnaudited NAV and Proposed Final Dividend
21st Feb 20233:10 pmRNSUnaudited Net Asset Value, Proposed Final Dividend
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 202310:17 amRNSDirector/PDMR Shareholding
8th Feb 20239:44 amRNSIssue of Equity
3rd Feb 20233:12 pmRNSProvisional Net Asset Value
23rd Nov 20224:53 pmRNSTransaction in Own Shares
10th Nov 20223:33 pmRNSNet Asset Value(s)
9th Nov 20223:02 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.